Some Claims Against Abbott Labs Proceed in Depakote Case

Federal drug labeling law preempts claims that Abbott Laboratories inadequately warned that its anti-epilepsy drug Depakote could cause developmental delays in the children of women who took it while pregnant, but other claims by an Ohio woman may proceed, a federal trial court said (Rheinfrank v. Abbott Labs., 2015 BL 256486, S.D. Ohio, 1:13-cv-00144-SJD, 8/10/15).

Pamela Rheinfrank, who alleges her daughter suffers developmental and other medical problems, raised fact questions on the adequacy of the Depakote label in other respects, Judge Susan J. Dlott of the U.S. District Court for the Southern District of Ohio said Aug. ...